about
Data-driven approach to generating achievable dose-volume histogram objectives in intensity-modulated radiotherapy planning.Dose-volume-related dysphagia after constrictor muscles definition in head and neck cancer intensity-modulated radiation treatment.Parotid gland shrinkage during IMRT predicts the time to Xerostomia resolutionHPV-related oropharyngeal carcinoma with Overt Level II and/or III metastases at presentation: The risk of subclinical disease in ipsilateral levels IB, IV and V.Volumetric change of human papillomavirus-related neck lymph nodes before, during, and shortly after intensity-modulated radiation therapy.Pattern and predictors of volumetric change of parotid glands during intensity modulated radiotherapy.Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future?Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer.What is changing in radiotherapy for the treatment of locally advanced nonsmall cell lung cancer patients? A review.Surprising complete response of intramedullary spinal cord metastasis from breast cancer: a case report and literature review.Radiotherapy in patients with connective tissue diseases.Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer.Radiotherapy in patients with HIV: current issues and review of the literature.Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.Synchronous bilateral breast cancer irradiation: clinical and dosimetrical issues using volumetric modulated arc therapy and simultaneous integrated boost.Simultaneous integrated bilateral breast and nodal irradiation with volumetric arc therapy: case report and literature review.From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?Cachexia induces head and neck changes in locally advanced oropharyngeal carcinoma during definitive cisplatin and image-guided volumetric-modulated arc radiation therapy.Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary toxicity.Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly Patients: Feasibility and Clinical Preliminary ResultsCone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response.Early changes of parotid density and volume predict modifications at the end of therapy and intensity of acute xerostomia.SmartArc-based volumetric modulated arc therapy for oropharyngeal cancer: a dosimetric comparison with both intensity-modulated radiation therapy and helical tomotherapy.Dosimetric predictors of dysphonia after intensity-modulated radiotherapy for oropharyngeal carcinoma.Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy.Hippocampal dose during Linac-based stereotactic radiotherapy for brain metastases: An observational study.Letter: Volumetric Arc Therapy (RapidArc) vs Gamma Knife Radiosurgery for Multiple Brain Metastases: Not Only a Dosimetric Issue.Regarding Ening et al. Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification.18F-Fluorodeoxyglucose-PET/CT in locally advanced head and neck cancer can influence the stage migration and nodal radiation treatment volumes.Impact of 18F-Choline PET/CT in the Decision-Making Strategy of Treatment Volumes in Definitive Prostate Cancer Volumetric Modulated Radiation Therapy.Comorbidities and intensity-modulated radiotherapy with simultaneous integrated boost in elderly breast cancer patients.Stereotactic ablative radiation therapy for brain metastases with volumetric modulated arc therapy and flattening filter free delivery: feasibility and early clinical results.Dosimetrics of intracranial stereotactic radiosurgery: Only "an exercise of style"?Predictors of PEG dependence after IMRT±chemotherapy for oropharyngeal cancer.A two-variable linear model of parotid shrinkage during IMRT for head and neck cancer.Linac-based VMAT radiosurgery for multiple brain lesions: comparison between a conventional multi-isocenter approach and a new dedicated mono-isocenter technique.An update on radiation therapy in head and neck cancers.Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by 18FDG-PET/CT.Nasal cavity reirradiation: a challenging case for comparison between proton therapy and volumetric modulated arc therapy.Volumetric change of selected organs at risk during IMRT for oropharyngeal cancer.
P50
Q33676457-75AC3612-6BB1-44FD-BD11-60CDD989E86EQ34568221-DC76A389-DA5B-4CA3-944A-87B4378F9840Q35016369-4800F963-5590-4726-99AA-FBBC34B9AF76Q36416456-A6269827-68B2-45CD-85CA-05A7F3942755Q37023773-9C8D01CE-21D4-4058-9B9A-6F65C99CA423Q37314916-06788A75-E3C1-458A-B66D-03F05B13A2C5Q38367507-2B0A63D9-66F4-4B12-A65E-A766D074A0BFQ38435885-600A337D-5465-4CF1-A1E5-D48D9993C72CQ38711723-5342A1E5-E953-430E-A0B9-F3AD2EB21688Q38749154-CA97B589-AA6F-48CF-964D-FE076E79A2ADQ38773196-1C6E96B5-5839-45CF-B3ED-0785C9637BC7Q38857880-2F0FB7A7-D064-4ACC-B69A-140A32646347Q38870545-CD55510B-152A-4689-A830-A5FB2188EBC7Q38942326-69136222-26C5-4227-9B34-D1D8FBD7EC51Q38948817-C72D772D-6450-4130-A619-853131F5DE25Q38975115-BB9ABB2A-B3C5-477A-895E-2EE1D5204CF3Q39041541-36745F01-2E87-461D-8487-C54FE8B0C55CQ39856469-ED0F1966-C81B-4D24-936D-D63EA85C345EQ40701137-AE847279-877F-4259-8CCB-5FC0AB8268BFQ42042375-389C13E8-5A66-4F69-A15C-A3B120EA078FQ42116312-30004A3F-A0A6-4B90-975B-05B7A4970A3FQ43696064-E003EB8F-B4DD-4CB4-8BE6-CD968FC440E4Q44979267-4962BC14-834B-4279-B5F3-F6ACFA55A06CQ46752100-69E66EF7-6975-49D8-8844-BFAD5D4F00E4Q47364748-9CAA5F84-05D3-401B-96B4-75EEE2612440Q48095675-BCB5E1A8-E1E7-46F4-A289-DD5C658F8E7CQ48194812-ABF6B9A5-BD15-49AC-AFC1-E1AAE111297AQ48311803-70233C4F-93C9-49FE-A0F0-76F3CD19A584Q48679846-119A794A-60AE-492C-BC06-807128E11734Q49039176-3E5C4642-B45F-4605-A6DE-2C5E4068337BQ50517201-24CC3113-2013-459E-8269-7D14ACD039CFQ50697335-E4404B5E-7966-4CDF-A48B-BE29E870C0ACQ50870326-AD9CA069-E145-4E85-AA9B-2B07D3610E97Q51233394-AA806094-2596-401C-A3A8-95F8D91D72D4Q51725319-21826923-6991-4FAD-8902-88CFC53B9911Q51744229-3581740E-DE58-4246-A0C3-D09E0716E845Q52683184-B36CC046-A868-46E7-83E1-4DF28AD5954AQ52953787-1537C219-53D9-463F-ACA5-35617A27DBF7Q52999792-3031C59B-4F3E-4EF2-831C-100728C53C58Q53245280-895B2D8C-2F28-4964-A12A-DCDC2B8E3901
P50
description
researcher ORCID ID = 0000-0002-4307-3440
@en
wetenschapper
@nl
name
Francesco Ricchetti
@ast
Francesco Ricchetti
@en
Francesco Ricchetti
@es
Francesco Ricchetti
@nl
type
label
Francesco Ricchetti
@ast
Francesco Ricchetti
@en
Francesco Ricchetti
@es
Francesco Ricchetti
@nl
prefLabel
Francesco Ricchetti
@ast
Francesco Ricchetti
@en
Francesco Ricchetti
@es
Francesco Ricchetti
@nl
P106
P1153
35290857700
P21
P31
P496
0000-0002-4307-3440